Real-time Estimate
Cboe BZX
12:07:07 2024-06-13 pm EDT
|
5-day change
|
1st Jan Change
|
0.098
USD
|
-5.77%
|
|
-17.25%
|
-77.45%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
31.81
|
16.22
|
122.4
|
77.23
|
20.66
|
11.48
|
Enterprise Value (EV)
1 |
4.084
|
3.391
|
12.46
|
-17.22
|
-14.22
|
23.13
|
P/E ratio
|
-1.09
x
|
-0.79
x
|
-3.29
x
|
-2.16
x
|
-0.47
x
|
-0.25
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.49
x
|
5.32
x
|
41.5
x
|
36.6
x
|
3.24
x
|
1.64
x
|
EV / Revenue
|
0.7
x
|
1.11
x
|
4.23
x
|
-8.15
x
|
-2.23
x
|
3.31
x
|
EV / EBITDA
|
-0.24
x
|
-0.18
x
|
-0.51
x
|
0.52
x
|
0.33
x
|
-0.67
x
|
EV / FCF
|
-0.27
x
|
-0.67
x
|
-0.8
x
|
1.06
x
|
0.46
x
|
-1.25
x
|
FCF Yield
|
-366%
|
-149%
|
-126%
|
93.9%
|
219%
|
-80.2%
|
Price to Book
|
1.05
x
|
1.18
x
|
1.04
x
|
0.69
x
|
0.28
x
|
0.37
x
|
Nbr of stocks (in thousands)
|
4,637
|
4,877
|
22,833
|
25,404
|
25,661
|
26,082
|
Reference price
2 |
6.860
|
3.325
|
5.360
|
3.040
|
0.8051
|
0.4403
|
Announcement Date
|
3/28/19
|
3/30/20
|
3/25/21
|
3/11/22
|
3/31/23
|
4/26/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
5.794
|
3.049
|
2.948
|
2.113
|
6.383
|
6.995
|
EBITDA
1 |
-17.23
|
-19.16
|
-24.59
|
-32.93
|
-42.5
|
-34.47
|
EBIT
1 |
-17.46
|
-19.4
|
-24.93
|
-33.54
|
-45.64
|
-42.03
|
Operating Margin
|
-301.43%
|
-636.11%
|
-845.51%
|
-1,587.31%
|
-715.02%
|
-600.9%
|
Earnings before Tax (EBT)
1 |
-17.58
|
-20.34
|
-26.38
|
-35.55
|
-47.15
|
-42.33
|
Net income
1 |
-15.73
|
-20.02
|
-26.05
|
-35.07
|
-43.43
|
-45.22
|
Net margin
|
-271.56%
|
-656.51%
|
-883.65%
|
-1,659.95%
|
-680.46%
|
-646.44%
|
EPS
2 |
-6.299
|
-4.210
|
-1.630
|
-1.408
|
-1.700
|
-1.736
|
Free Cash Flow
1 |
-14.95
|
-5.053
|
-15.67
|
-16.18
|
-31.11
|
-18.56
|
FCF margin
|
-258.12%
|
-165.73%
|
-531.53%
|
-765.87%
|
-487.31%
|
-265.32%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/19
|
3/30/20
|
3/25/21
|
3/11/22
|
3/31/23
|
4/26/24
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
---|
Net sales
1 |
0.6131
|
0.2124
|
0.051
|
0.0589
|
0.0799
|
0.7659
|
0.6578
|
0.7231
|
4.848
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-12.05
|
-7.477
|
-9.713
|
-9.497
|
-15.5
|
-
|
-14.32
|
-11.06
|
-6.435
|
Operating Margin
|
-1,964.66%
|
-3,519.7%
|
-19,052.73%
|
-16,134.81%
|
-19,397.1%
|
-
|
-2,176.38%
|
-1,529.43%
|
-132.74%
|
Earnings before Tax (EBT)
1 |
-13.75
|
-8.19
|
-10.26
|
-13.31
|
-15.39
|
-
|
-14.53
|
-11.21
|
-6.507
|
Net income
1 |
-13.56
|
-8.121
|
-10.16
|
-13
|
-12.15
|
-
|
-13.89
|
-13.13
|
-5.408
|
Net margin
|
-2,212.26%
|
-3,822.89%
|
-19,924.07%
|
-22,086.31%
|
-15,204.55%
|
-
|
-2,111.96%
|
-1,816.06%
|
-111.55%
|
EPS
2 |
-0.5400
|
-0.3200
|
-0.4000
|
-0.5100
|
-0.4800
|
-
|
-0.5300
|
-0.5000
|
-0.2100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/22
|
5/16/22
|
8/10/22
|
11/14/22
|
3/31/23
|
5/15/23
|
8/14/23
|
11/20/23
|
4/26/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
11.7
|
Net Cash position
1 |
27.7
|
12.8
|
110
|
94.5
|
34.9
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.338
x
|
Free Cash Flow
1 |
-15
|
-5.05
|
-15.7
|
-16.2
|
-31.1
|
-18.6
|
ROE (net income / shareholders' equity)
|
-92.1%
|
-93.9%
|
-41%
|
-31.1%
|
-47.6%
|
-82.9%
|
ROA (Net income/ Total Assets)
|
-37.7%
|
-38%
|
-20.8%
|
-17.1%
|
-25.3%
|
-33.8%
|
Assets
1 |
41.77
|
52.61
|
125.5
|
205.1
|
171.6
|
133.8
|
Book Value Per Share
2 |
6.530
|
2.810
|
5.150
|
4.410
|
2.880
|
1.200
|
Cash Flow per Share
2 |
4.770
|
1.870
|
0.4800
|
0.3100
|
0.3300
|
0.0100
|
Capex
1 |
0.59
|
0.27
|
0.34
|
1.9
|
20.1
|
1.99
|
Capex / Sales
|
10.24%
|
8.7%
|
11.46%
|
90.15%
|
315.17%
|
28.39%
|
Announcement Date
|
3/28/19
|
3/30/20
|
3/25/21
|
3/11/22
|
3/31/23
|
4/26/24
|
|
1st Jan change
|
Capi.
|
---|
| -76.38% | 10.28M | | +21.44% | 82.93B | | +13.33% | 9.15B | | +48.35% | 4.65B | | -20.52% | 4.58B | | +7.99% | 4.07B | | +9.54% | 2.24B | | -25.72% | 2.21B | | +12.16% | 2.03B | | -41.98% | 1.82B |
Specialty & Advanced Pharmaceuticals
|